RANI Rani Therapeutics Holdings Inc - Ordinary Shares Class A

$RANI Does Rani have short-term expansion plans? Yes, Rani Therapeutics has active and concrete expansion plans for the short and medium term. ​Production Automation: Following its inclusion in the ETP, Rani is specifically focusing on automating its vertically integrated manufacturing process to scale capsule production from clinical trial volumes to commercial-scale manufacturing. ​Capacity and Facility Expansion: Rani is expanding its manufacturing capacity to produce its own drugs and serve as a CDMO/manufacturing partner for major pharmaceutical companies looking to formulate their biologic drugs into the RaniPill. ​Pipeline Expansion (including Obesity): Rani is rapidly expanding its clinical programs, including the development of the RaniPill for obesity treatments (RT-114 GLP-1/GLP-2 dual agonist) and large molecules like antibodies.

$RANI Wat happens is the stock price fails to rise above one dollar? Rani Therapeutics is facing a tight timeline to regain Nasdaq compliance and avoid a potential delisting. ​If the stock price fails to organically rise above $1.00 through positive clinical news or investor confidence in time, the company has concrete options available: ​Requesting an extension: If the initial 180-day grace period expires without compliance, Rani can apply for a second 180-day extension, provided theymeet all other Nasdaq listing requirements and state their intention to cure the deficiency. ​Executing a reverse stock split: This serves as the fastest and most common emergency option. By consolidating shares (for example, combining 10 existing shares into 1 new share), the stock price immediately increases tenfold, placing Rani comfortably back above the $1.00 threshold. ​Let us hope management will reserve a reverse stock split as a last resort.... LET US RISE AND SHINE !!!!

$RANI Surged, Chugai's earnings have! Driven by strong exports and high royalties, it is. Up 14.1% to ¥1.07 trillion, nine-month revenue reached. Third-quarter net profit by 29.1% to ¥143 billion jumped, with a 50.1% operating margin, hmmm.

$RANI $LLY 100k traded..whatever traded from 88 cents to 58 cents are very low volume. Can shoot up quickly. Easy BO target!!!

$RANI shorts desperate to cover at low levels but no one is selling. Not even 100k volume. Still 7.12 million shares to cover…easily $2- $3.

$RANI is leading my undervalued under a dollar list. PT $8.50, currently waiting on Nov 9, 2026: Nasdaq deadline. The company has until November 9, 2026 to get back above the dollar minimum bid price. If it misses, it may get another 180 days by transferring to the Nasdaq Capital Market. That route requires stating an intent to do a reverse stock split if needed, so expect one. (Rani Therapeutics Holdings, Inc. - Form 8-K - FY2026 +2) RT-114 data: more Phase 1a data by end of 2026, and a Phase 1b repeat-dose study in patients with obesity starting by end of 2026, with results in 2027. (rttnews) Chugai milestone payments: about $18M in technology-transfer milestones expected, plus up to $57M in development milestones. (itiger) (sec) Leadership Mir Imran: founder, Executive Chairman Talat Imran: CEO since June 2021, with the executive team since 2014 (ranitherapeutics) Nicholas Maestas: CFO , hired June 2026 Mir Hashim, PhD: Chief Scientific Officer Alireza Javadi, PhD: Chief Tech O

$RANI needs to pull a rabbit out of a hat pronto. Is the son of the Elon Musk of biotech a success or flop? We'll soon find out.

$RANI there’s a reason for AI stock to fall which are trading at 50x and above. But why this one is going down.

$RANI la scadenza della conformità è il 09 novembre e questi non rilasciano nessun comunicato. INCREDIBILE!!!

$RANI Cathie Wood dimentica le crypto: all-in su energia e biotech con decine di milioni di movimenti.

$RANI take a look at $SFHS to see what kind of movement this stock could get if it gets a 180 day extension from NASDAQ.

$RANI what's your prediction by nov 9th, maintianing 10 straight days of global compliance, downgrading to captital or RS?